Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN

Stoneridge Investment Partners LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 2,360 shares of the biopharmaceutical company’s stock, valued at approximately $1,327,000.

Several other large investors also recently modified their holdings of REGN. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $31,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $38,000. Berbice Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its position in Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 35 shares during the period. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on REGN shares. BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Evercore ISI lifted their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a research report on Thursday. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Finally, Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $627.00 to $860.00 in a research note on Wednesday, January 7th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $794.70.

Insider Buying and Selling

In other news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is owned by insiders.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha previews Regeneron’s Q4 and expects an earnings beat and a strong 2026, maintaining a Buy rating and noting the shares have rallied >16% since the author’s prior note — this supports upside if results meet or exceed guidance. Read More.
• Positive Sentiment: Zacks says Regeneron has the right setup to beat upcoming earnings (Earnings “ESP”/estimates upside), which could trigger further upside if the company reports above-consensus results. Read More.
• Positive Sentiment: Evercore ISI raised its price target on REGN from $750 to $875 and kept an “outperform” call — a material analyst upgrade that increases implied upside and can support buying interest. Read More.
• Positive Sentiment: MarketBeat aggregation (reported on DefenseWorld/American Banking News) shows an average analyst rating of “Moderate Buy” across ~28 brokerages, indicating broad analyst conviction that could limit downside absent a negative print. Read More.
• Neutral Sentiment: Reminders that Regeneron will release quarterly earnings on Friday — serves as the immediate event risk/reward driver; expect heightened volume and larger intraday moves around the report. Read More.
• Neutral Sentiment: Zacks compares REGN with Illumina (ILMN) on valuation — useful context for investors weighing sector alternatives, but not an immediate catalyst for REGN alone. Read More.
• Neutral Sentiment: A Zacks piece highlights two medical names that could beat earnings (including REGN), which reinforces market attention on earnings-season upside but is not new company-specific data. Read More.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $753.55 on Friday. The company has a market capitalization of $79.20 billion, a price-to-earnings ratio of 18.04, a PEG ratio of 1.96 and a beta of 0.39. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock’s 50-day simple moving average is $755.38 and its 200-day simple moving average is $643.73. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter last year, the company earned $12.46 EPS. The firm’s quarterly revenue was up .9% on a year-over-year basis. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.